Sort by
Refine Your Search
-
Program
-
Field
-
inhouse developed long-acting GLP-1 receptor agonist, Efsubaglutide alfa , has achieved regulatory approval and market access in China representing a major milestone in biologics innovation originating from
-
problems in human health, CIMR has adopted a cutting-edge, multidisciplinary approach, bringing together scientists, doctors, entrepreneurs, and investors throughout the scoping and development
-
research in focused ultrasound therapy, aiming to achieve breakthroughs in acoustic physics, ultrasound biology, multimodal imaging, intelligent treatment, and clinical big data. Our mission is to develop
-
problems in human health, CIMR has adopted a cutting-edge, multidisciplinary approach, bringing together scientists, doctors, entrepreneurs, and investors throughout the scoping and development
-
the T-cell perspective, and develop novel chemical immunotherapeutics with clinical potential. Successful candidates will join an interdisciplinary team at the interface of chemistry, immunology, and